NCT00127647View on ClinicalTrials.gov

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,375

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Rhinitis, Allergic, Seasonal
Interventions
DRUG

montelukast sodium

montelukast sodium; 5 mg, 10 mg QD 2-weeks.

DRUG

Comparator: pranlukast

Pranlukast 225 mg BID 2-weeks.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00127647 - An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) | Biotech Hunter | Biotech Hunter